Carestream Health Introduces New Mobile X-Ray Device
The DRX-Rise Mobile X-ray System reportedly combines optimal image quality with enhanced maneuverability and ease of use for radiologists.
With the promise of artificial intelligence (AI)-powered image processing and features that promote workflow productivity and maneuverability, Carestream Health has launched the DRX-Rise Mobile X-ray System.
One of the features of the DRX-Rise Mobile X-ray System is Carestream Health’s AI-propelled ImageView Software, which facilitates image quality and dosing efficiency through robust image processing, according to Carestream Health.
The company said other attributes of the new X-ray system include in-bin detector charging, two touchscreen displays and new drive capabilities that help ensure optimal maneuverability and positioning at a patient’s bedside.
“The DRX-Rise Mobile X-ray System delivers high-end features that support the most critical needs in medical imaging: exceptional image quality for confident diagnosis; workflow-accelerating attributes for productivity; and a more comfortable imaging experience for patients – all without significantly impacting capital budget,” noted Jordan Berry, the global marketing manager for Carestream Health.
(Editor’s note: For related content, see “Autonomous AI Shows Nearly 27 Percent Higher Sensitivity than Radiology Reports for Abnormal Chest X-Rays” and “Canon Medical Launches New CT and X-Ray Modalities at ECR 2023.”)
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
